Edgewise Therapeutics Inc.
06/05/2026 | Press release | Distributed by Public on 06/05/2026 14:34
Proxy Results (Form 8-K)
| Item 5.07. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
Edgewise Therapeutics, Inc. (the "Company") held its Annual Meeting of stockholders (the "Annual Meeting") on June 4, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.
Proposal 1: Election of three Class II Directors
| Name of Director | For | Withheld | |||||
| Laura Brege | 87,300,827 | 3,822,867 | |||||
| Badreddin Edris, Ph.D. | 64,082,681 | 27,041,013 | |||||
| Jonathan Root, M.D. | 59,213,781 | 31,909,913 | |||||
Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
| For | Against | Abstain | |||||
| 99,637,228 | 1,123 | 578,031 |
The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers
| For | Against | Abstain | |||||
| 87,055,111 | 3,491,326 | 577,257 |
The stockholders approved, on an advisory and non-binding basis, the compensation of the Company's named executive officers.
Edgewise Therapeutics Inc. published this content on June 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 05, 2026 at 20:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]